2026 H1 -tulosraportti
12 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 619 | - | - | ||
| 21 117 | - | - | ||
| 5 164 | - | - | ||
| 3 719 | - | - | ||
| 9 214 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenA chapter of sorrow 🥴 Are we going further down into the valley now that short positions are increasing, I wonder?
As long as the rights issue is not completed, there will hardly be any big upturn, hope they hurry up with this rights issue so we can rather look forward to news, results, price targets and lots of other fun stuff! It will be exciting to hear about the time perspective on the USA venture, and even more how the sales of AlphaOne develop throughout the autumn/winter. It will be an incredibly exciting autumn! But when will this part 2 of the issue be completed?? Want to be done with it!
·3 t sittenA little about AdvanCell, Thor's customer. At ProsTIC26 in Melbourne last week, they showed three things about ADVC001, against the spread of prostate cancer. First, how alpha kills. The radiation hits the DNA in the cancer cell within less than a millimeter. Healthy tissue around it largely remains intact. The second and third posters are what hospitals care about. Staff receive a low dose. The patient is discharged after approx. three hours. Today, with Lu-177, the patient is isolated. The isotope lives for over six days. Toilet, bedding, distance from family. With Pb-212, the radiation dies quickly. Then nuclear medicine can operate more like a regular infusion, not a radiation hotel. Advancell's generator, which converts Th-228 to Pb-212, received a design award on September 1. Thor produces the raw material the generator is fed with. https://www.red-dot.org/project/advancell-212pb-generator-63944 ESMO is coming on October 23. Updated Phase 1b numbers from TheraPb, first proper long-term follow-up and confirmation of the dose in Phase 2. Not the start of Phase 3. Phase 3 will come when Phase 2 is read, earliest late 2027, more realistically 2028. BioPharm today highlighted the agreement AdvanCell has with 48Hour Discovery for a new Pb-212 program against gastrointestinal cancer, planned for clinic in 2027. https://www.biopharminternational.com/view/advancell-targets-gi-cancer-with-peptide-driven-lead-212-radiotherapy This means more isotope over time, possibly a more extended contract is coming. AdvanCell already buys Th-228 from Thor. More programs and later Phase 3 mean more generators out of Herøya. The numbers they have are exactly what the FDA is looking for. Serious illness. 30 percent do not respond to Pluvicto. 80 percent PSA50 and 100 percent response in measurable tumors in the small Phase 1b group, without dose-limiting toxicity. My thought is that there will be fast track here at the FDA after ESMO, if the long-term data holds up. Fast Track does not cut the studies themselves. It cuts queues and errors. At the end: Priority Review is 6 months instead of 10. Four months saved, if the application is otherwise correct. Along the way: more meetings with the FDA. Then design flaws are caught before Phase 2 or 3 is complete. Then it can be half to a full year. If you combine that with the four months at the finish line, you can at best talk about up to a year and a half faster to market. Oncoinvent has it on Radspherin. Alpha Tau (DRTS) has Breakthrough Device on Alpha DaRT, which is the fast track for equipment. Same stuff, just done a little differently, Ra-224 and Pb-212 both get a boost towards the market. Thor produces the raw material for both isotopes.
- ·4 t sittenPerspective released new figures on VMT-α-NET. It is Pb-212 against neuroendocrine tumors in the stomach, intestines, and pancreas. They have followed the patients for 22 months. In the late images, the tumor is smaller than in the early ones. More go from stable disease to actual shrinkage the longer they are followed. The effect builds up, it's not a short flash at the first check-up. They also research VMT01 against melanoma, alone and together with immunotherapy. They have an agreement with DOE, not with Thor. The point is the field. When such data comes, more dare to bet on Pb-212. Then more Th-228 is needed. Thor already supplies Oncoinvent for the same type of NET disease. https://www.linkedin.com/posts/catx-radiopharmaceuticals-targetedoncology-ugcPost-7503102614855815168-m609/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY&utm_campaign=share_via3 t sittenhttps://perspectivetherapeutics.com/technology/manufacturing-logistics If the demand for Pb-212 grows rapidly, Perspective, Actinium, Bayer, AstraZeneca, Novartis, and other TAT players will need more starting materials. The availability of Th-228 could tighten if the deployment of new sources fails to keep pace with demand; this is a prime opportunity for Thorin to step in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 H1 -tulosraportti
12 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenA chapter of sorrow 🥴 Are we going further down into the valley now that short positions are increasing, I wonder?As long as the rights issue is not completed, there will hardly be any big upturn, hope they hurry up with this rights issue so we can rather look forward to news, results, price targets and lots of other fun stuff! It will be exciting to hear about the time perspective on the USA venture, and even more how the sales of AlphaOne develop throughout the autumn/winter. It will be an incredibly exciting autumn! But when will this part 2 of the issue be completed?? Want to be done with it!
- ·3 t sittenA little about AdvanCell, Thor's customer. At ProsTIC26 in Melbourne last week, they showed three things about ADVC001, against the spread of prostate cancer. First, how alpha kills. The radiation hits the DNA in the cancer cell within less than a millimeter. Healthy tissue around it largely remains intact. The second and third posters are what hospitals care about. Staff receive a low dose. The patient is discharged after approx. three hours. Today, with Lu-177, the patient is isolated. The isotope lives for over six days. Toilet, bedding, distance from family. With Pb-212, the radiation dies quickly. Then nuclear medicine can operate more like a regular infusion, not a radiation hotel. Advancell's generator, which converts Th-228 to Pb-212, received a design award on September 1. Thor produces the raw material the generator is fed with. https://www.red-dot.org/project/advancell-212pb-generator-63944 ESMO is coming on October 23. Updated Phase 1b numbers from TheraPb, first proper long-term follow-up and confirmation of the dose in Phase 2. Not the start of Phase 3. Phase 3 will come when Phase 2 is read, earliest late 2027, more realistically 2028. BioPharm today highlighted the agreement AdvanCell has with 48Hour Discovery for a new Pb-212 program against gastrointestinal cancer, planned for clinic in 2027. https://www.biopharminternational.com/view/advancell-targets-gi-cancer-with-peptide-driven-lead-212-radiotherapy This means more isotope over time, possibly a more extended contract is coming. AdvanCell already buys Th-228 from Thor. More programs and later Phase 3 mean more generators out of Herøya. The numbers they have are exactly what the FDA is looking for. Serious illness. 30 percent do not respond to Pluvicto. 80 percent PSA50 and 100 percent response in measurable tumors in the small Phase 1b group, without dose-limiting toxicity. My thought is that there will be fast track here at the FDA after ESMO, if the long-term data holds up. Fast Track does not cut the studies themselves. It cuts queues and errors. At the end: Priority Review is 6 months instead of 10. Four months saved, if the application is otherwise correct. Along the way: more meetings with the FDA. Then design flaws are caught before Phase 2 or 3 is complete. Then it can be half to a full year. If you combine that with the four months at the finish line, you can at best talk about up to a year and a half faster to market. Oncoinvent has it on Radspherin. Alpha Tau (DRTS) has Breakthrough Device on Alpha DaRT, which is the fast track for equipment. Same stuff, just done a little differently, Ra-224 and Pb-212 both get a boost towards the market. Thor produces the raw material for both isotopes.
- ·4 t sittenPerspective released new figures on VMT-α-NET. It is Pb-212 against neuroendocrine tumors in the stomach, intestines, and pancreas. They have followed the patients for 22 months. In the late images, the tumor is smaller than in the early ones. More go from stable disease to actual shrinkage the longer they are followed. The effect builds up, it's not a short flash at the first check-up. They also research VMT01 against melanoma, alone and together with immunotherapy. They have an agreement with DOE, not with Thor. The point is the field. When such data comes, more dare to bet on Pb-212. Then more Th-228 is needed. Thor already supplies Oncoinvent for the same type of NET disease. https://www.linkedin.com/posts/catx-radiopharmaceuticals-targetedoncology-ugcPost-7503102614855815168-m609/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY&utm_campaign=share_via3 t sittenhttps://perspectivetherapeutics.com/technology/manufacturing-logistics If the demand for Pb-212 grows rapidly, Perspective, Actinium, Bayer, AstraZeneca, Novartis, and other TAT players will need more starting materials. The availability of Th-228 could tighten if the deployment of new sources fails to keep pace with demand; this is a prime opportunity for Thorin to step in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 619 | - | - | ||
| 21 117 | - | - | ||
| 5 164 | - | - | ||
| 3 719 | - | - | ||
| 9 214 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 H1 -tulosraportti
12 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenA chapter of sorrow 🥴 Are we going further down into the valley now that short positions are increasing, I wonder?As long as the rights issue is not completed, there will hardly be any big upturn, hope they hurry up with this rights issue so we can rather look forward to news, results, price targets and lots of other fun stuff! It will be exciting to hear about the time perspective on the USA venture, and even more how the sales of AlphaOne develop throughout the autumn/winter. It will be an incredibly exciting autumn! But when will this part 2 of the issue be completed?? Want to be done with it!
- ·3 t sittenA little about AdvanCell, Thor's customer. At ProsTIC26 in Melbourne last week, they showed three things about ADVC001, against the spread of prostate cancer. First, how alpha kills. The radiation hits the DNA in the cancer cell within less than a millimeter. Healthy tissue around it largely remains intact. The second and third posters are what hospitals care about. Staff receive a low dose. The patient is discharged after approx. three hours. Today, with Lu-177, the patient is isolated. The isotope lives for over six days. Toilet, bedding, distance from family. With Pb-212, the radiation dies quickly. Then nuclear medicine can operate more like a regular infusion, not a radiation hotel. Advancell's generator, which converts Th-228 to Pb-212, received a design award on September 1. Thor produces the raw material the generator is fed with. https://www.red-dot.org/project/advancell-212pb-generator-63944 ESMO is coming on October 23. Updated Phase 1b numbers from TheraPb, first proper long-term follow-up and confirmation of the dose in Phase 2. Not the start of Phase 3. Phase 3 will come when Phase 2 is read, earliest late 2027, more realistically 2028. BioPharm today highlighted the agreement AdvanCell has with 48Hour Discovery for a new Pb-212 program against gastrointestinal cancer, planned for clinic in 2027. https://www.biopharminternational.com/view/advancell-targets-gi-cancer-with-peptide-driven-lead-212-radiotherapy This means more isotope over time, possibly a more extended contract is coming. AdvanCell already buys Th-228 from Thor. More programs and later Phase 3 mean more generators out of Herøya. The numbers they have are exactly what the FDA is looking for. Serious illness. 30 percent do not respond to Pluvicto. 80 percent PSA50 and 100 percent response in measurable tumors in the small Phase 1b group, without dose-limiting toxicity. My thought is that there will be fast track here at the FDA after ESMO, if the long-term data holds up. Fast Track does not cut the studies themselves. It cuts queues and errors. At the end: Priority Review is 6 months instead of 10. Four months saved, if the application is otherwise correct. Along the way: more meetings with the FDA. Then design flaws are caught before Phase 2 or 3 is complete. Then it can be half to a full year. If you combine that with the four months at the finish line, you can at best talk about up to a year and a half faster to market. Oncoinvent has it on Radspherin. Alpha Tau (DRTS) has Breakthrough Device on Alpha DaRT, which is the fast track for equipment. Same stuff, just done a little differently, Ra-224 and Pb-212 both get a boost towards the market. Thor produces the raw material for both isotopes.
- ·4 t sittenPerspective released new figures on VMT-α-NET. It is Pb-212 against neuroendocrine tumors in the stomach, intestines, and pancreas. They have followed the patients for 22 months. In the late images, the tumor is smaller than in the early ones. More go from stable disease to actual shrinkage the longer they are followed. The effect builds up, it's not a short flash at the first check-up. They also research VMT01 against melanoma, alone and together with immunotherapy. They have an agreement with DOE, not with Thor. The point is the field. When such data comes, more dare to bet on Pb-212. Then more Th-228 is needed. Thor already supplies Oncoinvent for the same type of NET disease. https://www.linkedin.com/posts/catx-radiopharmaceuticals-targetedoncology-ugcPost-7503102614855815168-m609/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY&utm_campaign=share_via3 t sittenhttps://perspectivetherapeutics.com/technology/manufacturing-logistics If the demand for Pb-212 grows rapidly, Perspective, Actinium, Bayer, AstraZeneca, Novartis, and other TAT players will need more starting materials. The availability of Th-228 could tighten if the deployment of new sources fails to keep pace with demand; this is a prime opportunity for Thorin to step in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 619 | - | - | ||
| 21 117 | - | - | ||
| 5 164 | - | - | ||
| 3 719 | - | - | ||
| 9 214 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt